Compassionate Access of the Miltenyi Device for CD34+ Cell Selection
Primary Purpose
Blood And Marrow Transplantation
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
CD34 Positive Stem Cell Infusion
Miltenyi device
Sponsored by

About this trial
This is an interventional treatment trial for Blood And Marrow Transplantation focused on measuring Blood And Marrow Transplantation, Stem cell transplantation, SCT, Poor graft function, CD34+ cell infusion
Eligibility Criteria
Inclusion Criteria:
1) Patients who have poor or no graft function post stem cell transplantation.
Exclusion Criteria:
N/A
Sites / Locations
- University of Texas MD Anderson Cancer CenterRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
CD34 Positive Stem Cell Infusion
Arm Description
Participants infused by vein with around 1 - 4 million/kg CD34+ selected cells. If the first infusion is not effective, an additional infusion may be given 4 - 6 weeks after the first infusion.
Outcomes
Primary Outcome Measures
Increased Graft Function after Stem Cell Transplantation (SCT)
Blood drawn for signs of graft versus host disease (GVHD).
Secondary Outcome Measures
Full Information
NCT ID
NCT02438904
First Posted
May 6, 2015
Last Updated
August 10, 2023
Sponsor
M.D. Anderson Cancer Center
1. Study Identification
Unique Protocol Identification Number
NCT02438904
Brief Title
Compassionate Access of the Miltenyi Device for CD34+ Cell Selection
Official Title
Compassionate Access of the Miltenyi Device for CD34+ Cell Selection
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 6, 2015 (Actual)
Primary Completion Date
May 1, 2025 (Anticipated)
Study Completion Date
May 1, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
M.D. Anderson Cancer Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
Objectives:
Primary Objective
To provide compassionate access to the Miltenyi device for CD34+ cell infusions to patients who experience poor graft function after stem cell transplantation (SCT).
Detailed Description
The therapy that you will receive involves you being given an infusion of CD34 positive stem cells.
Below is a detailed explanation of the therapeutic procedures that will be performed.
CD34 positive stem cells infusion:
The CD34 positive stem cells are collected from a donor's blood. The blood cells go through CD34 (stem cell) selection process that collects the stem cells that are needed for the infusion. This process collects the early immune cells your body will need to regrow your immune system, and makes sure that other cells will not be infused. This process will decrease (but not eliminate completely) the other types of cells. If you agree to receive this treatment, the CD34 cells will then be infused into your body.
The CD34 positive cells will be given by vein in either an inpatient or outpatient treatment area. The infusion will last about 10-30 minutes.
Before the infusion, you will receive Tylenol (acetaminophen) by mouth and Benadryl (diphenhydramine hydrochloride) by mouth or vein about 30-60 minutes before the infusion. These drugs will be used to help lower the risk of side effects. If side effects occur during the infusion, the doses of the drugs may be adjusted (up or down) until the symptoms are gone. Also, if you have side effects during the infusion, you will be observed for 2 hours after it is given or until the symptoms have stopped completely (whichever is later). During this time, your blood pressure, heart rate, breathing rate, temperature, and the level of oxygen in your blood will be checked every 15-30 minutes.
About 4-6 weeks after the first infusion, you may receive an additional infusion, if your doctor thinks it is needed.
Clinic Visits:
One (1) time a week after the infusion, until your doctor thinks it is no longer clinically needed, you will have the following tests:
Blood (about 1 teaspoon) will be drawn for routine tests.
You will be checked for signs of graft versus host disease (GVHD). Symptoms of GVHD include skin rash, nausea, vomiting, diarrhea, and abnormal liver function.
This is an investigational study. The CD34 positive stem cell infusion to help boost cell counts is not FDA approved.
Up to 75 patients will be enrolled on this treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Blood And Marrow Transplantation
Keywords
Blood And Marrow Transplantation, Stem cell transplantation, SCT, Poor graft function, CD34+ cell infusion
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
75 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
CD34 Positive Stem Cell Infusion
Arm Type
Experimental
Arm Description
Participants infused by vein with around 1 - 4 million/kg CD34+ selected cells. If the first infusion is not effective, an additional infusion may be given 4 - 6 weeks after the first infusion.
Intervention Type
Biological
Intervention Name(s)
CD34 Positive Stem Cell Infusion
Intervention Description
Participants infused by vein with around 1 - 4 million/kg CD34+ selected cells.
Intervention Type
Device
Intervention Name(s)
Miltenyi device
Other Intervention Name(s)
CliniMACS device
Intervention Description
Miltenyi device is used for CD34+ cell infusions) to patients who experience poor graft function after stem cell transplantation (SCT).
Primary Outcome Measure Information:
Title
Increased Graft Function after Stem Cell Transplantation (SCT)
Description
Blood drawn for signs of graft versus host disease (GVHD).
Time Frame
4 weeks
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
1) Patients who have poor or no graft function post stem cell transplantation.
Exclusion Criteria:
N/A
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Elizabeth Shpall, MD
Phone
713-745-2161
Email
eshpall@mdanderson.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Elizabeth Shpall, MD
Organizational Affiliation
M.D. Anderson Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Texas MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
12. IPD Sharing Statement
Links:
URL
http://www.mdanderson.org
Description
University of Texas MD Anderson Cancer Center
Learn more about this trial
Compassionate Access of the Miltenyi Device for CD34+ Cell Selection
We'll reach out to this number within 24 hrs